Stevia / LOHAS Stock Alert: GLG Life Tech Corporation (TSX: GLG) (OTC: GLGLF) Announces First Quarter 2014 Financial Results

Vancouver, B.C. - May 13, 2014 (Investorideas.com Newswire) GLG Life Tech Corporation (TSX: GLG) (OTC: GLGLF) ("GLG" or the "Company"), a vertically-integrated leader in the agricultural and commercial development of high-quality stevia and other natural sweeteners, announces financial results for the quarter ended March 31, 2014.

2014 FIRST QUARTER HIGHLIGHTS

New sales strategy delivers Top Line Sales Growth
Revenue for the three months ended March 31, 2014, was $4.7 million, an increase of 44% compared to $3.2 million in stevia-related revenue for the same period last year. We achieved this increase primarily by pursuing sales of higher purity stevia extracts to international customers that generate monthly recurring revenues.

Gold Resource Corp (GORO)

The trading levels of GORO exploded on Tuesday after the company delivered strong operating results.

For the first quarter ended March 31, 2014, GORO reported net income of $7.1 million, or $0.13 per share, production of 23,734 ounces precious metal gold equivalent and decreased its total cash cost by 18% over the first quarter of 2013.

Gold Resource Corp (GORO) is a mining company focused on production and pursuing development of gold and silver projects that feature low operating costs and produce high returns on capital.

MONTREAL, QC - May 12, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma, Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that a “Notice of Allowance” for the patent application covering its lead antitumor compound, Adva-27a, has recently been issued in Canada. The allowed claims in Canada are nearly identical to those already issued in the United States where Sunshine Biopharma is the exclusive licensee. Sunshine Biopharma has previously announced preclinical results showing that Adva-27a has excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of multidrug resistant cancer cells including breast cancer cells and pancreatic cancer cells. Adva-27a appears to be unique in its ability to destroy multidrug resistant cancer cells. Sunshine Biopharma is moving forward with the next steps in the development of Adva-27a which include GMP manufacturing, IND-enabling studies and Phase I clinical trials.

SHELTON, CT - May 12, 2014 (Investorideas.com Newswire) NXT-ID, Inc. (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, is pleased to announce that the first series of 30 second spots on CNBC for its next generation smart wallet, Wocket™ , will start airing May 14th. The ads will air on Squawk Box, Squawk on the Street and Street Signs.

The "Get to know Wocket™ " ad campaign is part of a comprehensive marketing roll- out including the May 28th press conference and marketing event to be held at the Plaza Hotel in New York City ( 3:00 - 5:00 PM ). Advance ordering for Wocket™ will start at 5:00 pm May 28th at http://www.wocketwallet.com/.